Company intelligence / Profile preview

Satsuma Pharmaceuticals

Durham, North Carolina, USsatsumarx.com ↗

Ownership: Private
Development stage: NDA

Overview

FDA-approved Atzumi™ (formerly STS101) in April2025 as first DHE nasal powder using SMART Platform. Demonstrated rapid/sustained DHE concentrations in clinical trials across >10,000 treated migraine attacks.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

dihydroergotamine

NDA

Indications: episodic migraine

Partnerships

SNBL(device technology licensor)

Beyond the preview

Go deeper on Satsuma Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Satsuma Pharmaceuticals.

Explore the full profile